This has allowed companies in this industry to profit from the growing epidemic by targeting obesity-related medical issues such as diabetes, high blood pressure, cholesterol, heart disease, stroke and sleep apnea.
Healthcare companies make up 83% of SLIM’s holdings and 55% of its holdings include companies located in the United States. The largest population affected by obesity resides within the United States. The SLIM ETF takes advantage of this market and the potential prosperity that comes from companies fighting this crisis.
“If we focus on the fundamental issues we have a growing population, while at the same time also having an increasing percentage of the population becoming obese. This is exponential. This is extremely promising since any divergence or change in how obesity is treated would most probably not affect the price of the ETF negatively, while a continuing trend of obesity treatment & obesity related purchases (bariatric surgery, dieting pills, mobility scooters) would affect the price positively. At the same time, increases in obesity would fuel the demand for medication from complications – high blood pressure, diabetes – and would likely keep pharma stocks up,” says Seeking Alpha.
For more information on the ETF industry, visit our current affairs category.